EMA
EUROPEAN MEDICINES AGENCY

EMA Veterinary Info Day 2026

Update from the CVMP ADRA temporary Working Party (tWP)

Damien Bouchard, Chair of the Dosage Review and Adjustment of Established Veterinary Antibiotics temporary Working Party (ADRA tWP)

EMA
EUROPEAN MEDICINES AGENCY

Background information

CVMP Reflection paper

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 January 2021
EMA/CVMP/84977/2017
Committee for Medicinal Products for Veterinary Use (CVMP)

Reflection paper on dose review and adjustment of established veterinary antibiotics in the context of SPC harmonisation

Adopted by CVMP for release for consultation	19 July 2018
Start of public consultation	27 July 2018
End of consultation (deadline for comments)	31 January 2019
Adopted by CVMP	10 December 2020

Keywords	antimicrobial resistance (AMR), summary of product characteristics (SPC), Dose review and adjustment, pharmacokinetic/pharmacodynamic (PK/PD) modelling, target animal safety (TAS), withdrawal periods (WP) and the environmental risk assessment (ERA)

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged.

Reflection paper
[EMA/CVMP/84977 5/2017](#)
(2018-2020)

*«Pilot project on feasibility to use **non-experimental approaches to review and adjust the dosing regimen** of established veterinary antibiotics.»*

Priorisation of substances


EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 January 2021
EMA/CVMP/84977/2017
Committee for Medicinal Products for Veterinary Use (CVMP)

Reflection paper on dose review and adjustment of established veterinary antibiotics in the context of SPC harmonisation

Adopted by CVMP for release for consultation	19 July 2018
Start of public consultation	27 July 2018
End of consultation (deadline for comments)	31 January 2019
Adopted by CVMP	10 December 2020

Keywords	antimicrobial resistance (AMR), summary of product characteristics (SPC), Dose review and adjustment, pharmacokinetic/pharmacodynamic (PK/PD) modelling, target animal safety (TAS), withdrawal periods (WP) and the environmental risk assessment (ERA)

Reflection paper
[EMA/CVMP/84977 5/2017](#)
(2018-2020)


EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

ADRA project – info session for veterinary pharmaceutical industry

22 May 2025, 14:30 – 16:00 (CEST)
Virtual meeting

The ADRA (**D**osage **R**eview and **A**djustment of selected veterinary **A**ntibiotics) project builds on the related 2017 CVMP reflection paper, acknowledging that the authorised product information for some established veterinary antibiotics may not be fully aligned with current scientific knowledge.

Led by the Committee for Veterinary Medicinal Products (CVMP) and EMA, the ADRA project will focus on reviewing dosage regimens for established veterinary antibiotics through non-experimental approaches, with the goal to:

- refine the dosage regimens of those veterinary antibiotics to ensure the prudent use of antibiotics in veterinary medicine.
- evaluate the implications of any dose review on withdrawal periods, target animal safety and environmental risk assessment without necessitating the generation of new study data.

Interested participants are invited to read the discussion document (link) and submit questions in advance.

ADRA Priority list
Working Group

(2024-2025)

2024

CVMP questionnaire to stakeholders

(FVE, EARS-Vet, VetCAST, EURL, AnimalHealthEurope, AccessVetMed, NCAs)

Priorisation of substances


EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 January 2021
EMA/CVMP/84977/2017
Committee for Medicinal Products for Veterinary Use (CVMP)

Reflection paper on dose review and adjustment of established veterinary antibiotics in the context of SPC harmonisation

Adopted by CVMP for release for consultation	19 July 2018
Start of public consultation	27 July 2018
End of consultation (deadline for comments)	31 January 2019
Adopted by CVMP	10 December 2020

Keywords	antimicrobial resistance (AMR), summary of product characteristics (SPC), Dose review and adjustment, pharmacokinetic/pharmacodynamic (PK/PD) modelling, target animal safety (TAS), withdrawal periods (WP) and the environmental risk assessment (ERA)

Reflection paper
EMA/CVMP/84977 5/2017
(2018-2020)


EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

ADRA project – info session for veterinary pharmaceutical industry

22 May 2025, 14:30 – 16:00 (CEST)
Virtual meeting

The ADRA (**D**osage **R**eview and **A**djustment of selected veterinary **A**ntibiotics) project builds on the related 2017 CVMP reflection paper, acknowledging that the authorised product information for some established veterinary antibiotics may not be fully aligned with current scientific knowledge.

Led by the Committee for Veterinary Medicinal Products (CVMP) and EMA, the ADRA project will focus on reviewing dosage regimens for established veterinary antibiotics through non-experimental approaches, with the goal to:

- refine the dosage regimens of those veterinary antibiotics to ensure the prudent use of antibiotics in veterinary medicine.
- evaluate the implications of any dose review on withdrawal periods, target animal safety and environmental risk assessment without necessitating the generation of new study data.

Interested participants are invited to read the discussion document (link) and submit questions in advance.

ADRA Priority list
Working Group

(2024-2025)

2025

Establishment of a priority list of antibiotic susbtances



ADRA temporary Working Party


EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 January 2021
EMA/CVMP/84977 5/2017
Committee for Medicinal Products for Veterinary Use (CVMP)

Reflection paper on dose review and adjustment of established veterinary antibiotics in the context of SPC harmonisation

Adopted by CVMP for release for consultation	19 July 2018
Start of public consultation	27 July 2018
End of consultation (deadline for comments)	31 January 2019
Adopted by CVMP	10 December 2020

Keywords	antimicrobial resistance (AMR), summary of product characteristics (SPC), Dose review and adjustment, pharmacokinetic/pharmacodynamic (PK/PD) modelling, target animal safety (TAS), withdrawal periods (WP) and the environmental risk assessment (ERA)

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged.

Reflection paper EMA/CVMP/84977 5/2017 (2018-2020)


EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

ADRA project – info session for veterinary pharmaceutical industry

22 May 2025, 14:30 – 16:00 (CEST)
Virtual meeting

The ADRA (**D**osage **R**eview and **A**djustment of selected veterinary **A**ntibiotics) project builds on the related 2017 CVMP reflection paper, acknowledging that the authorised product information for some established veterinary antibiotics may not be fully aligned with current scientific knowledge.

Led by the Committee for Veterinary Medicinal Products (CVMP) and EMA, the ADRA project will focus on reviewing dosage regimens for established veterinary antibiotics through non-experimental approaches, with the goal to:

- refine the dosage regimens of those veterinary antibiotics to ensure the prudent use of antibiotics in veterinary medicine.
- evaluate the implications of any dose review on withdrawal periods, target animal safety and environmental risk assessment without necessitating the generation of new study data.

Interested participants are invited to read the discussion document (link) and submit questions in advance.

ADRA Priority list Working Group

(2024-2025)


EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

16 July 2025
EMA/CVMP/182608/2025
Committee for Veterinary Medicinal Products (CVMP)

Mandate, objectives and rules of procedure for the CVMP temporary Working Party (tWP) on the ADRA project

1. General considerations

According to Article 139 of Regulation (EU) 2019/6 and to the Committee for Veterinary Medicinal Products ("CVMP") rules of procedure, temporary working parties may be established when work of a temporary or ad-hoc nature is required such as preparation of proposals on a specific scientific topic, or preparation of responses to specific questions raised by the Committee.

The CVMP has identified the need to support particular scientific or technical matters that require specialised knowledge for the 'Dosage Review and Adjustment of established Antibiotics (ADRA)' project. To achieve this, it is necessary to consult a group of experts with relevant expertise: pharmacokinetic/pharmacodynamic (PK/PD) modelling on antibiotics, efficacy of antibiotics, target animal safety ("TAS"), withdrawal periods/withdrawal period modelling, and environmental risk assessment ("ERA").

The CVMP has therefore established a temporary Working Party ("tWP") to deal with specific aspects of the assessment and respond to CVMP questions related to the ADRA project.

The group will be reporting to the Committee via its Chairperson, who will keep the appointed rapporteur and co-rapporteur informed for the respective scientific advice(s) conducted under Article 141(1)(i) of Regulation (EU) 2019/6.

The tasks identified by the CVMP should be included in the work plan of each working party to be adopted by the Committee.

2. Mandate and objectives

The temporary Working Party on the ADRA project (hereafter "ADRA tWP") is established to provide relevant expertise and input to the CVMP on matters related to the ADRA project including, but not limited to, the following tasks:

- Provide ad-hoc support to the (co-)rapporteurs on matters related to the preparation of the respective scientific advices under Article 141(1)(i) of Regulation (EU) 2019/6. The aim of the scientific advices would be to review and refine the dosage regimen (i.e., dose, frequency and

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.

ADRA temporary Working Party

(2025-2026)

EMA
EUROPEAN MEDICINES AGENCY

ADRA tWP

Mandate

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

16 July 2025
EMA/CVMP/182608/2025
Committee for Veterinary Medicinal Products (CVMP)

Mandate, objectives and rules of procedure for the CVMP temporary Working Party (tWP) on the ADRA project

1. General considerations

According to Article 139 of Regulation (EU) 2019/6 and to the Committee for Veterinary Medicinal Products ("CVMP") rules of procedure, temporary working parties may be established when work of a temporary or ad-hoc nature is required such as preparation of proposals on a specific scientific topic, or preparation of responses to specific questions raised by the Committee.

The CVMP has identified the need to support particular scientific or technical matters that require specialised knowledge for the 'Dosage Review and Adjustment of established Antibiotics (ADRA)' project. To achieve this, it is necessary to consult a group of experts with relevant expertise: pharmacokinetic/pharmacodynamic (PK/PD) modelling on antibiotics, efficacy of antibiotics, target animal safety ("TAS"), withdrawal periods/withdrawal period modelling, and environmental risk assessment ("ERA").

The CVMP has therefore established a temporary Working Party ("tWP") to deal with specific aspects of the assessment and respond to CVMP questions related to the ADRA project.

The group will be reporting to the Committee via its Chairperson, who will keep the appointed rapporteur and co-rapporteur informed for the respective scientific advice(s) conducted under Article 141(1)(i) of Regulation (EU) 2019/6.

The tasks identified by the CVMP should be included in the work plan of each working party to be adopted by the Committee.

2. Mandate and objectives

The temporary Working Party on the ADRA project (hereafter "ADRA tWP") is established to provide relevant expertise and input to the CVMP on matters related to the ADRA project including, but not limited to, the following tasks:

- Provide ad-hoc support to the (co-)rapporteurs on matters related to the preparation of the respective scientific advices under Article 141(1)(i) of Regulation (EU) 2019/6. The aim of the scientific advices would be to review and refine the dosage regimen (i.e., dose, frequency and

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union

ADRA temporary Working Party

(2025-2026)

Objective

Provide ad-hoc support related to the preparation of the respective **scientific advice procedures under Article 141(1)(i)** of Regulation (EU) 2019/6 to review:

- ***the dosage regimen*** *(i.e., dose, frequency and treatment duration) ensuring the* ***continued efficacy and safety*** *of antibiotics and* ***minimising antimicrobial resistance****.*
- *the* ***implications*** *that a change in the dosage regimen might have for* ***TAS, withdrawal period, and ERA****.*

Mandate

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

16 July 2025
EMA/CVMP/182608/2025
Committee for Veterinary Medicinal Products (CVMP)

Mandate, objectives and rules of procedure for the CVMP temporary Working Party (tWP) on the ADRA project

1. General considerations

According to Article 139 of Regulation (EU) 2019/6 and to the Committee for Veterinary Medicinal Products ("CVMP") rules of procedure, temporary working parties may be established when work of a temporary or ad-hoc nature is required such as preparation of proposals on a specific scientific topic, or preparation of responses to specific questions raised by the Committee.

The CVMP has identified the need to support particular scientific or technical matters that require specialised knowledge for the 'Dosage Review and Adjustment of established Antibiotics (ADRA)' project. To achieve this, it is necessary to consult a group of experts with relevant expertise: pharmacokinetic/pharmacodynamic (PK/PD) modelling on antibiotics, efficacy of antibiotics, target animal safety ("TAS"), withdrawal periods/withdrawal period modelling, and environmental risk assessment ("ERA").

The CVMP has therefore established a temporary Working Party ("tWP") to deal with specific aspects of the assessment and respond to CVMP questions related to the ADRA project.

The group will be reporting to the Committee via its Chairperson, who will keep the appointed rapporteur and co-rapporteur informed for the respective scientific advice(s) conducted under Article 141(1)(i) of Regulation (EU) 2019/6.

The tasks identified by the CVMP should be included in the work plan of each working party to be adopted by the Committee.

2. Mandate and objectives

The temporary Working Party on the ADRA project (hereafter "ADRA tWP") is established to provide relevant expertise and input to the CVMP on matters related to the ADRA project including, but not limited to, the following tasks:

- Provide ad-hoc support to the (co-)rapporteurs on matters related to the preparation of the respective scientific advices under Article 141(1)(i) of Regulation (EU) 2019/6. The aim of the scientific advices would be to review and refine the dosage regimen (i.e., dose, frequency and

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.

ADRA temporary Working Party

(2025-2026)

Composition

ADRA tWP is a **multidisciplinary working party**, composed of a limited number of experts. It includes 2-3 members per relevant area of expertise:

- *Pharmacokinetic/pharmacodynamic (PK/PD) modelling*
- *Efficacy of antibiotics*
- *Target animal safety (TAS)*
- *Withdrawal periods/withdrawal period modelling*
- *Environmental risk assessment (ERA)*

ADRA tWP will report to the CVMP, keeping the appointed rapporteur and co-rapporteur informed.

First assessment under Art. 141(1)(i)


EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

16 July 2025
EMA/CVMP/182608/2025
Committee for Veterinary Medicinal Products (CVMP)

Mandate, objectives and rules of procedure for the CVMP temporary Working Party (tWP) on the ADRA project

1. General considerations

According to Article 139 of Regulation (EU) 2019/6 and to the Committee for Veterinary Medicinal Products ("CVMP") rules of procedure, temporary working parties may be established when work of a temporary or ad-hoc nature is required such as preparation of proposals on a specific scientific topic, or preparation of responses to specific questions raised by the Committee.

The CVMP has identified the need to support particular scientific or technical matters that require specialised knowledge for the 'Dosage Review and Adjustment of established Antibiotics (ADRA)' project. To achieve this, it is necessary to consult a group of experts with relevant expertise: pharmacokinetic/pharmacodynamic (PK/PD) modelling on antibiotics, efficacy of antibiotics, target animal safety ("TAS"), withdrawal periods/withdrawal period modelling, and environmental risk assessment ("ERA").

The CVMP has therefore established a temporary Working Party ("tWP") to deal with specific aspects of the assessment and respond to CVMP questions related to the ADRA project.

The group will be reporting to the Committee via its Chairperson, who will keep the appointed rapporteur and co-rapporteur informed for the respective scientific advice(s) conducted under Article 141(1)(i) of Regulation (EU) 2019/6.

The tasks identified by the CVMP should be included in the work plan of each working party to be adopted by the Committee.

2. Mandate and objectives

The temporary Working Party on the ADRA project (hereafter "ADRA tWP") is established to provide relevant expertise and input to the CVMP on matters related to the ADRA project including, but not limited to, the following tasks:

- Provide ad-hoc support to the (co-)rapporteurs on matters related to the preparation of the respective scientific advices under Article 141(1)(i) of Regulation (EU) 2019/6. The aim of the scientific advices would be to review and refine the dosage regimen (i.e., dose, frequency and

ADRA temporary Working Party

(2025-2026)

For 2026…

Art. 141(1)(i):
''CVMP shall provide scientific advice on the use of antimicrobials and antiparasitics in animals to minimise the occurrence of resistance in the Union, and update that advice when needed''



First scientific advice – concerned VMPs

''Amoxicillin (single active substance) _ pig _ oral use (in drinking water or in feed) – respiratory indications''

First assessment under Art. 141(1)(i)

For 2026



Start of review concerning veterinary medicines containing amoxicillin

Call for data closed on 19 February 2026

- ***From MAHs***
- ***From NCAs***
- ***From VetCAST***
- ***From literature***

First assessment under Art. 141(1)(i)

Overview of data collected

Top priority of the tWP

1. PK and PD data extraction.
2. Validation of the PK/PD model.
3. Computation of the dosage regimen.

PK data for dosage regimen

- 35 studies containing **individual plasma raw data** corresponding to 430 animals (62 IV + 368 Oral)
  - **from MAH:** Ceva, Sogeval, Virbac, V.M.D, Emdoka, Dopharma, MSD, Belapharm
  - **from literature:** Anadon et al., 2006, ; Reyns et al. 2007, Krasucka et al., 2010; Menotta et al., 2012; Li et al., 2025, Rey et al., 2014 + personnal data collection from Toutain et al.,

PK data for withdrawal period

- 18 studies containing **individual tissue raw data** corresponding to 157 animals
  - **from MAH:** Ceva, Virbac, V.M.D, Emdoka, Dopharma, MSD, Fatro, Vet Planet, Pharmagal, Vetoquinol

First assessment under Art. 141(1)(i)

Overview of data collected

Top priority of the tWP

1. PK and PD data extraction.
2. Validation of the PK/PD model.
3. Computation of the dosage regimen.

PD data for dosage regimen

- **From literature and EUCAST database:** data related to MICs distributions for relevant target pathogens
- **From VetCAST :** data related to Time-Kill Curves

Considerations related to PK/PD models

- **PD component** in relation to the indication and relevant target pathogens (e.g. MIC distribution, ECOFF)
- **PK/PD index and target values** in relation to the therapeutic objective
- **Additional considerations**
  - dosing frequency
  - duration of treatment
  - Risk of resistance (*e.g.* TKC, MPC)

First assessment under Art. 141(1)(i)

For 2026

- VMPs containing amoxicillin in pigs for respiratory infections -

PK/PD integration for dose review and adjustment

PK modelling for withdrawal period adjustment

scientific review approaches to address TAS and ERA

First assessment under Art. 141(1)(i)

For 2026

- VMPs containing amoxicillin in pigs for respiratory infections -

PK/PD integration for dose review and adjustment

PK modelling for withdrawal period adjustment

_ *approach using T1/2(final phase)*

_ *PBPK approach*

First assessment under Art. 141(1)(i)

For 2026

- VMPs containing amoxicillin in pigs for respiratory infections -

PK/PD integration for dose review and adjustment

PK modelling for withdrawal period adjustment

Scientific review approaches to address TAS and ERA

First assessment under Art. 141(1)(i)

For 2026

- VMPs containing amoxicillin in pigs for respiratory infections -

Data from MAHs has also been received to support the reassessment once the dose will be refined:

- ***ERA*** _ *recalculation of the PECs / RQs for the different environmental compartments*
- ***TAS*** _ *comparisons based on the data and margin of safety initially provided in MA dossiers*

Scientific review approaches to address TAS and ERA

First assessment under Art. 141(1)(i)

First scientific advice to be adopted by the CVMP in **Q1 2027**

–

VMPs containing amoxicillin in pigs for respiratory infections

- Refined dosages in the PI of VMPs will further **ensure the prudent use of antibiotics** in veterinary medicine.
- The review should aim to **preserve efficacy and availability while avoiding unnecessary loss of VMPs or indications**.

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Thank you

Send a question to the European Medicines Agency

Follow us